The scientist’s investigation covers issues in Internal medicine, Endocrinology, Insulin, Gastric inhibitory polypeptide and Incretin. Internal medicine is often connected to Gastroenterology in his work. His research related to Glucagon-like peptide-1, Glucagon, Diabetes mellitus, Gastrointestinal hormone and Peptide hormone might be considered part of Endocrinology.
His study in Stimulation extends to Insulin with its themes. His work deals with themes such as Ingestion, Carbohydrate metabolism and Endogeny, which intersect with Gastric inhibitory polypeptide. His Incretin research incorporates themes from Hormone, Antiserum and Glucose clamp technique.
His primary areas of investigation include Internal medicine, Endocrinology, Insulin, Gastric inhibitory polypeptide and Gastroenterology. His research brings together the fields of Diabetes mellitus and Internal medicine. While the research belongs to areas of Endocrinology, Werner Creutzfeldt spends his time largely on the problem of Cholecystokinin, intersecting his research to questions surrounding Secretin and Antagonist.
His Insulin study frequently draws connections between adjacent fields such as Ingestion. The Gastric inhibitory polypeptide study combines topics in areas such as Postprandial, Endogeny and Secretion. His Gastroenterology research includes themes of Disease and Endocrine system.
Werner Creutzfeldt mainly focuses on Internal medicine, Endocrinology, Insulin, Gastroenterology and Glucagon-like peptide-1. His Pancreatic disease, Pancreatitis, Pancreas, Gastric acid and Peptide hormone study are his primary interests in Internal medicine. His work investigates the relationship between Endocrinology and topics such as Cholecystokinin that intersect with problems in Secretagogue.
The study incorporates disciplines such as Carcinoma, Disease, Gastrin and Endocrine system in addition to Gastroenterology. His study in Glucagon-like peptide-1 is interdisciplinary in nature, drawing from both Metformin, Gastric emptying, Acarbose and Hormone, Glucagon. His Incretin research is multidisciplinary, incorporating perspectives in Pharmacology and Renal function.
His scientific interests lie mostly in Internal medicine, Endocrinology, Glucagon-like peptide-1, Glucagon and Insulin. His research investigates the connection between Internal medicine and topics such as Gastroenterology that intersect with issues in Endocrine system. Diabetes mellitus, Gastric inhibitory polypeptide, Gastrointestinal hormone, Peptide hormone and Gastric acid are among the areas of Endocrinology where Werner Creutzfeldt concentrates his study.
His work in Glucagon-like peptide-1 addresses issues such as Hormone, which are connected to fields such as Receptor, Appetite, Pharmacology, Islet and Enterogastrone. His biological study spans a wide range of topics, including Acarbose and Gastric emptying. His study in Pancreatic hormone, Incretin and Glucagon secretion falls under the purview of Insulin.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.
M A Nauck;M M Heimesaat;C Orskov;J J Holst.
Journal of Clinical Investigation (1993)
Reduced incretin effect in type 2 (non-insulin-dependent) diabetes.
M. Nauck;F. Stöckmann;R. Ebert;W. Creutzfeldt.
Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.
M. A. Nauck;N. Kleine;C. Orskov;J. J. Holst.
Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses
M A Nauck;E Homberger;E G Siegel;R C Allen.
The Journal of Clinical Endocrinology and Metabolism (1986)
The incretin concept today.
Early ERCP and Papillotomy Compared with Conservative Treatment for Acute Biliary Pancreatitis
Ulrich R. Fölsch;Rolf Nitsche;Rainer Lüdtke;Reinhard A. Hilgers.
The New England Journal of Medicine (1997)
Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients.
B Willms;J Werner;J J Holst;C Orskov.
The Journal of Clinical Endocrinology and Metabolism (1996)
Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations.
M A Nauck;E Bartels;C Orskov;R Ebert.
The Journal of Clinical Endocrinology and Metabolism (1993)
Natural course in chronic pancreatitis. Pain, exocrine and endocrine pancreatic insufficiency and prognosis of the disease.
Paul Georg Lankisch;Annette Löhr-Happe;Jutta Otto;Werner Creutzfeldt.
Glucagonostatic Actions and Reduction of Fasting Hyperglycemia by Exogenous Glucagon-Like Peptide I(7–36) amide in type I diabetic patients
Werner O C Creutzfeldt;Nicola Kleine;Berend Willms;Cathrine Ørskov.
Diabetes Care (1996)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: